Research programme: anti-cancer therapeutics - Sesen Bio

Drug Profile

Research programme: anti-cancer therapeutics - Sesen Bio

Alternative Names: Anti-PSMA humabody-deBouganin fusion proteins - Sesen Bio; Armed Antibodies™; NP-1 - Sesen Bio; VB 4011; VB 6901; VB-6008; VB-6011; VB-6050; VB-7756; VB1-008; VB1-050; VBX-008; VBX-011; VBX-050

Latest Information Update: 18 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Viventia Biotechnologies
  • Developer Sesen Bio
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Peptides; Recombinant fusion proteins
  • Mechanism of Action CD44 antigen modulators; Epithelial cell adhesion molecule modulators; Protein synthesis inhibitors; Ribosomal protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 16 May 2018 Eleven Biotherapeutics is now called Sesen Bio
  • 09 Apr 2018 Preclinical development is ongoing in cancer (9237323; Eleven Biotherapeutics Pipeline)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Canada (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top